Clinical Trial Update: Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating tinengotinib tablets in combination with fulvestrant for HR-positive, HER2-negative recurrent or metastatic breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Tinengotinib (tinengotinib)

Snippet

Sponsor: TransThera Sciences (Nanjing), Inc. | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING